President and CEO Michael Kamdar and CSO and cofounder J. William Efcavitch, Ph.D., talk with GEN EDGE about the company’s history and how their fully enzymatic synthesis technology can overcome the length, purity, and accuracy limitations of the chemical DNA synthesis method. The Fully Enzymatic Synthesis (FES™) technology by Molecular Assemblies employs a template-independent DNA polymerase, called terminal deoxynucleotidyl transferase (TdT), which has the ability to synthesize much longer DNA sequences with fewer errors. This two-step proprietary process uses aqueous non-toxic reagents, requires minimal post-synthesis processing, and can scale to longer DNA sequences.
Read the full article and Q&A here. Subscription may be required.
